Do analysts prefer TRVI or RDY?

Trevi Therapeutics currently has a consensus price target of $26.75, suggesting a potential upside of 46.56%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Trevi Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor TRVI or RDY?

In the previous week, Trevi Therapeutics had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 10 mentions for Trevi Therapeutics and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Trevi Therapeutics' score of 0.16 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRNX or TRVI?

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Crinetics Pharmaceuticals and 10 mentions for Trevi Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.66 beat Trevi Therapeutics' score of 0.16 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALKS or TRVI?

In the previous week, Alkermes had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 14 mentions for Alkermes and 10 mentions for Trevi Therapeutics. Alkermes' average media sentiment score of 0.81 beat Trevi Therapeutics' score of 0.16 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TRVI or LQDA?

In the previous week, Liquidia had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Liquidia and 10 mentions for Trevi Therapeutics. Liquidia's average media sentiment score of 0.99 beat Trevi Therapeutics' score of 0.16 indicating that Liquidia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRVI or LNTH?

In the previous week, Lantheus had 16 more articles in the media than Trevi Therapeutics. MarketBeat recorded 26 mentions for Lantheus and 10 mentions for Trevi Therapeutics. Lantheus' average media sentiment score of 0.52 beat Trevi Therapeutics' score of 0.16 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 9 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Trevi Therapeutics (TRVI) Competitors

$18.25 -0.26 (-1.39%)

As of 10:06 AM Eastern

Compare

TRVI vs. RDY, CRNX, ALKS, LQDA, and LNTH

Should you buy Trevi Therapeutics stock or one of its competitors? MarketBeat compares Trevi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevi Therapeutics include Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Alkermes (ALKS), Liquidia (LQDA), and Lantheus (LNTH). These companies are all part of the "pharmaceuticals" industry.

How does Trevi Therapeutics compare to Dr. Reddy's Laboratories?

Trevi Therapeutics (NASDAQ:TRVI) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Trevi Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Trevi Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

In the previous week, Trevi Therapeutics had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 10 mentions for Trevi Therapeutics and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Trevi Therapeutics' score of 0.16 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dr. Reddy's Laboratories	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Dr. Reddy's Laboratories	$3.58B	2.81	$456M	$0.44	27.42

Trevi Therapeutics currently has a consensus price target of $26.75, suggesting a potential upside of 46.56%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Trevi Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Trevi Therapeutics and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Trevi Therapeutics has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,158.71	-$465.32M	-$5.04	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Trevi Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Trevi Therapeutics' return on equity of -23.59% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Crinetics Pharmaceuticals presently has a consensus price target of $81.00, suggesting a potential downside of 3.70%. Trevi Therapeutics has a consensus price target of $26.75, suggesting a potential upside of 46.56%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Crinetics Pharmaceuticals and 10 mentions for Trevi Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.66 beat Trevi Therapeutics' score of 0.16 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crinetics Pharmaceuticals has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Summary

Trevi Therapeutics beats Crinetics Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Alkermes currently has a consensus target price of $54.56, indicating a potential upside of 11.94%. Trevi Therapeutics has a consensus target price of $26.75, indicating a potential upside of 46.56%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Alkermes has a net margin of 3.96% compared to Trevi Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Trevi Therapeutics	N/A	-23.59%	-22.64%

In the previous week, Alkermes had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 14 mentions for Alkermes and 10 mentions for Trevi Therapeutics. Alkermes' average media sentiment score of 0.81 beat Trevi Therapeutics' score of 0.16 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.67B	4.90	$241.66M	$0.38	128.27
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alkermes has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Summary

Alkermes beats Trevi Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Liquidia?

Trevi Therapeutics (NASDAQ:TRVI) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Trevi Therapeutics has higher earnings, but lower revenue than Liquidia. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Liquidia	$158.32M	50.08	-$68.92M	$0.14	636.88

Trevi Therapeutics presently has a consensus price target of $26.75, indicating a potential upside of 46.56%. Liquidia has a consensus price target of $86.18, indicating a potential downside of 3.34%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

In the previous week, Liquidia had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Liquidia and 10 mentions for Trevi Therapeutics. Liquidia's average media sentiment score of 0.99 beat Trevi Therapeutics' score of 0.16 indicating that Liquidia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a net margin of 7.74% compared to Trevi Therapeutics' net margin of 0.00%. Liquidia's return on equity of 46.82% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Liquidia	7.74%	46.82%	7.06%

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Trevi Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Summary

Liquidia beats Trevi Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Lantheus?

Trevi Therapeutics (NASDAQ:TRVI) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39

Trevi Therapeutics presently has a consensus target price of $26.75, suggesting a potential upside of 46.56%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 7.09%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

In the previous week, Lantheus had 16 more articles in the media than Trevi Therapeutics. MarketBeat recorded 26 mentions for Lantheus and 10 mentions for Trevi Therapeutics. Lantheus' average media sentiment score of 0.52 beat Trevi Therapeutics' score of 0.16 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	9 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.69% compared to Trevi Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Lantheus	17.69%	28.10%	14.35%

Trevi Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

Summary

Lantheus beats Trevi Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVI vs. The Competition

Export

Metric	Trevi Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.61B	$11.86B	$7.02B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-53.89	788.48	269.90	24.97
Price / Sales	N/A	968.97	659.13	107.89
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	12.76	10.37	11.29	6.44
Net Income	-$42.76M	$2.77B	$3.45B	$347.50M
7 Day Performance	1.97%	2.47%	3.56%	3.82%
1 Month Performance	2.31%	-1.08%	-0.57%	-0.37%
1 Year Performance	145.98%	191.49%	77.67%	23.81%

Trevi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVI Trevi Therapeutics	3.3137 of 5 stars	$18.25 -1.4%	$26.75 +46.6%	+149.5%	$2.61B	N/A	N/A	20	Earnings Report Analyst Forecast Gap Up
RDY Dr. Reddy's Laboratories	2.8546 of 5 stars	$12.17 +0.5%	N/A	-11.6%	$10.15B	$3.58B	27.65	27,527
CRNX Crinetics Pharmaceuticals	2.0313 of 5 stars	$83.92 +0.1%	$81.00 -3.5%	+213.1%	$8.85B	$7.70M	N/A	210	Earnings Report
ALKS Alkermes	3.3411 of 5 stars	$50.68 +2.0%	$54.56 +7.7%	+84.1%	$8.50B	$1.48B	133.27	2,050	Analyst Forecast
LQDA Liquidia	3.397 of 5 stars	$90.91 +2.9%	$86.18 -5.2%	+341.2%	$8.07B	$158.32M	648.34	50	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVI) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevi Therapeutics (TRVI) Competitors

TRVI vs. RDY, CRNX, ALKS, LQDA, and LNTH

How does Trevi Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Trevi Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Trevi Therapeutics compare to Alkermes?

Summary

How does Trevi Therapeutics compare to Liquidia?

Summary

How does Trevi Therapeutics compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevi Therapeutics (TRVI) Competitors

TRVI vs. RDY, CRNX, ALKS, LQDA, and LNTH

How does Trevi Therapeutics compare to Dr. Reddy's Laboratories?

Which has more risk and volatility, TRVI or RDY?

Is TRVI or RDY more profitable?

Does the media favor TRVI or RDY?

Do institutionals and insiders hold more shares of TRVI or RDY?

Which has preferable earnings and valuation, TRVI or RDY?

Do analysts prefer TRVI or RDY?

Summary

How does Trevi Therapeutics compare to Crinetics Pharmaceuticals?

Which has higher valuation and earnings, CRNX or TRVI?

Do institutionals & insiders have more ownership in CRNX or TRVI?

Is CRNX or TRVI more profitable?

Do analysts prefer CRNX or TRVI?

Does the media prefer CRNX or TRVI?

Which has more risk & volatility, CRNX or TRVI?

Summary

How does Trevi Therapeutics compare to Alkermes?

Do analysts recommend ALKS or TRVI?

Is ALKS or TRVI more profitable?

Does the media refer more to ALKS or TRVI?

Which has preferable valuation & earnings, ALKS or TRVI?

Do insiders & institutionals have more ownership in ALKS or TRVI?

Which has more risk & volatility, ALKS or TRVI?

Summary

How does Trevi Therapeutics compare to Liquidia?

Which has better earnings & valuation, TRVI or LQDA?

Do analysts prefer TRVI or LQDA?

Does the media prefer TRVI or LQDA?

Is TRVI or LQDA more profitable?

Do institutionals & insiders believe in TRVI or LQDA?

Which has more risk & volatility, TRVI or LQDA?

Summary

How does Trevi Therapeutics compare to Lantheus?

Do insiders and institutionals have more ownership in TRVI or LNTH?

Which has stronger earnings & valuation, TRVI or LNTH?

Do analysts rate TRVI or LNTH?

Does the media favor TRVI or LNTH?

Is TRVI or LNTH more profitable?

Which has more volatility and risk, TRVI or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools